Candriam S.C.A. Reata Pharmaceuticals Inc Transaction History

Candriam S.C.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$30.85 - $93.17 $165,880 - $500,975	5,377 New	5,377 $488,000
Q2 2021 Jul 20, 2021	SELL	$78.27 - $151.29 $11.9 Million - $23 Million	-151,707 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$102.03 - $184.62 $497,600 - $900,391	-4,877 Reduced 3.11%	151,707 $18.8 Million
Q2 2020 Jul 23, 2020	BUY	$126.3 - $176.56 $5.2 Million - $7.27 Million	41,184 Added 35.69%	156,584 $24.4 Million
Q4 2019 Jan 21, 2020	SELL	$74.57 - $217.92 $6.03 Million - $17.6 Million	-80,800 Reduced 41.18%	115,400 $24,000
Q3 2019 Oct 21, 2019	SELL	$71.26 - $95.75 $3.78 Million - $5.07 Million	-53,000 Reduced 21.27%	196,200 $16,000
Q1 2019 May 02, 2019	BUY	$51.9 - $101.79 $2.6 Million - $5.09 Million	50,000 Added 25.1%	249,200 $21.3 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $76.44 $195,040 - $305,760	4,000 Added 2.05%	199,200 $11.2 Million
Q3 2018 Nov 07, 2018	BUY	$35.64 - $92.06 $1.73 Million - $4.46 Million	48,500 Added 33.06%	195,200 $16 Million
Q2 2018 Aug 14, 2018	BUY	$19.94 - $40.96 $1.09 Million - $2.24 Million	54,700 Added 59.46%	146,700 $5.13 Million
Q4 2017 Feb 07, 2018	BUY	$22.39 - $33.27 $716,480 - $1.06 Million	32,000 Added 53.33%	92,000 $2.61 Million
Q3 2017 Nov 03, 2017	BUY	$26.29 - $31.88 $1.58 Million - $1.91 Million	60,000	60,000 $1.87 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.